Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$7.44 USD
+0.11 (1.50%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.43 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
TNGX 7.44 +0.11(1.50%)
Will TNGX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TNGX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TNGX
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates
TNGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
Wall Street Analysts Predict an 110.53% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know
How Much Upside is Left in Tango Therapeutics, Inc. (TNGX)? Wall Street Analysts Think 115.31%
Other News for TNGX
Cantor starts Tango Therapeutics with Overweight on tumor pipeline
Tango Therapeutics initiated with bullish view at Cantor Fitzgerald
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics Breaks Below 200-Day Moving Average - Notable for TNGX
Buy Rating Affirmed for Tango Therapeutics on Strong Pipeline and Financial Stability